Resource data sheet
Prev.
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR L858R

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.

Catalog number RDB15493
Resource name pENTER-EGFR L858R
Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, L858R in exon 21, EGFR-activating mutation.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : G to A substitution at 2618nt (Q, synonym) ; T to G substitution at 2830nt (L858R).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
Other clones in our bank

External Database
human EGFR

          Reference sequence
            
           

          Distribution information

          Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
          Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
          Ordering Please visit Information of Request for Distribution.[link] 
          Order form 
          [Credit Card Payment]  [Bank Transfer Payment]
          Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
          Remarks
          Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
          提供案内 (日本国内) [open/close]

          提供条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
          提供依頼 手続きの詳細は、「提供申込みについて[link]」をご覧ください。
          提供依頼書 [Word]
          提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
          備考
          Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

          Catalog # Resource name Shipping form Fee (non-profit org.)
          RDB15493 pENTER-EGFR L858R DNA solution

          Please review the QC test results indicated by check icon below as well as clone information before placing your order.

          How to cite this biological resource

          Materials & Methods section:

          The pENTER-EGFR L858R was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15493).

          Reference section:

          Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          Further references such as user reports and related articles (go to bottom)


          References and tips

          Featured content


          QC test results

          RIKEN BRC has sequenced portions of this material for quality test.
          Please review the QC test results indicated by check icon as well as clone information before placing your order.

          Test sheet RDB15493_A7K8p1-2.pdf check

          Nucleotide sequence of a portion of this resource (if available).

          Primer: rrnBT1ter_F2 (Pr0531)
          Region: rrnB T1 ter,attL1,insert 5'
          Sequence file: RDB15493_A7K8d.seq check
          >D04925A6_A7K8_2_rrnBT1ter_F2_F04_16_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NCCTTTCGTT TTNTTTGATG CCTGGCAGTT CCCTACTCTC
             61 GCGTTAACGC TAGCATGGAT GTTTTCCCAG TCACGACGTT GTAAAACGAC GGCCAGTCTT
            121 AAGCTCGGGC CCCAAATAAT GATTTTATTT TGACTGATAG TGACCTGTTC GTTGCAACAA
            181 ATTGATGAGC AATGCTTTTT TATAATGCCA ACTTTGTACA AAAAAGCAGG CTCCGCGGCC
            241 GCCCCCTTCA CCATGCGACC CTCCGGGACG GCCGGGGCAG CGCTCCTGGC GCTGCTGGCT
            301 GCGCTCTGCC CGGCGAGTCG GGCTCTGGAG GAAAAGAAAG TTTGCCAAGG CACGAGTAAC
            361 AAGCTCACGC AGTTGGGCAC TTTTGAAGAT CATTTTCTCA GCCTCCAGAG GATGTTCAAT
            421 AACTGTGAGG TGGTCCTTGG GAATTTGGAA ATTANNNATG TGCAGAGGAA TTATGATCTT
            481 TCCTTCTTAA AGACCATCCA GGAGGTGGCT GGTTATGTCC TCATTGCCCT CAACACAGTG
            541 GAGCGAATTC CTTTGGAAAA CCTGCAGATC ATCAGAGGAA ATATGTACTA CGAAAATTCC
            601 TATGCCTTAG CAGTCTTATC TAACTATGAT GCAAATAAAA CCGGACTGAA GGAGCTGCCC
            661 ATGAGAAATT TACAGGAAAT CCTGCATGGC GCCGTGCGGT TCAGCAACAA CCCTGCCCTG
            721 TGCAATGTGG AGAGCATCCA GTGGCGGGAC ATAGTCAGCA GTGACTTTCT CAGCAACATG
            781 TCGATGGACT TCCAGAACCA CCTGGGCAGC TGCCAAAAGT GTGATCCAAG CTGTCNNAAN
            841 GNNANCTGCT GGGGTGCANG NNANGANAAN TGCCAGAAAC TGANCAAANT CATCTGTGCC
            901 CAGCAGTGNN NCNGGNGCTG CCNNNGNAAN NNCCCCCANN NNNNGCNNNC NCAACCANNN
          961 NNNTNNNNNN NNNN
          //
          Primer: pDONR_R (Pr0071)
          Region: attL2,insert 3'
          Sequence file: RDB15493_A7K8e.seq check
          >D04925A6_A7K8_2_pDONR_R_H05_23_ABI24.ab1
              1 NNNNNNNNNN NNNNNNCNNT GNNNNTGTNA TACGACTCNC TATAGGGGAN ATCAGCTGGA
             61 TGGCAAATAA TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA AATTGATAAG
            121 CAATGCTTTC TTATAATGCC AACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT
            181 CATGCTCCAA TAAATTCACT GCTTTGTGGC GCGACCCTTA GGTATTCTGC ATTTTCAGCT
            241 GTGGAGCCCT TAAAGATGCC ATTTGGCTTG GCTTCCTTGG GAAAGAAGTC CTGCTGGTAG
            301 TCAGGGTTGT CCAGGCTAAT TTGGTGGCTG CCTTTCTGGG CCCAGTGGGC AGGGCTGTCG
            361 AATGTGCTGT TGACACAGGT GGGCTGGACA GTGTTGAGAT ACTCGGGGTT GCCCACTGCA
            421 GTGCTGTGGG GGTCCTGGTA GTGTGGGTCT CTGCTGGGCG CGGGGTTCAG AGGCTGATTG
            481 TGATAGACAG GATTCTGCAC AGAGCCAGCG GGCCTTTTGG GAACGGACTG GTTTATGTAT
            541 TCAGGCACTG GGAGGAAGGT GTCGTCTATG CTGTCCTCAG TCAAGGCGCC TGTGGGGTCT
            601 GAGCTGTATC GCTGCAAGAA GCTGTCTTCC TTGATGGGAC AGCTTTGCAG CCCATTTCTA
            661 TCAATGCAAG CCACGGTGGA ATTGTTGCTG GTTGCACTCA GAGAGCTCAN GANGGGAGTC
            721 CGTGACGTGG ANGGGCTGCT GAANAAGCCC TGCTGTGGGA NGANGTACTC GTCGGCATCC
            781 ACCACGTCGT CCATGTCTTC TTCATCCNTC NNGNCACGGT ANAAGTTGGA NTCTGTANGA
            841 NTTNNCAAAT GCATTCTTTC NTCCCCCCNG ANTGANAAGG NANCGCTNGG GGGTCNCGGG
            901 CCNNTTTNGG ANNANNTCNA TGANCNNNTC NNNGNANNNT TNGGNNNANN ATCTGCNNCT
          961 ATNNNNNNNN NN
          //
          Primer: EGFR-F5 (Pr0313)
          Region: insert mid (L858R)
          Sequence file: RDB15493_A7K8f.seq check
          >D04925A6_A7K8_2_EGFR-F5_F09_18_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNNGGNNGGT GGGGGCCCTC CTCTTGCTGC TGGTGGTGGC
             61 CCTGGGGNNC GGCCTCTTCA TGCGAAGGCG CCACATCGTT CGGAAGCGCA CGCTGCGGAG
            121 GCTGCTGCAG GAGAGGGAGC TTGTGGAGCC TCTTACACCC AGTGGAGAAG CTCCCAACCA
            181 AGCTCTCTTG AGGATCTTGA AGGAAACTGA ATTCAAAAAG ATCAAAGTGC TGGGCTCCGG
            241 TGCGTTCGGC ACGGTGTATA AGGGACTCTG GATCCCAGAA GGTGAGAAAG TTAAAATTCC
            301 CGTCGCTATC AAGGAATTAA GAGAAGCAAC ATCTCCGAAA GCCAACAAGG AAATCCTCGA
            361 TGAAGCCTAC GTGATGGCCA GCGTGGACAA CCCCCACGTG TGCCGCCTGC TGGGCATCTG
            421 CCTCACCTCC ACCGTGCAAC TCATCACGCA GCTCATGCCC TTCGGCTGCC TCCTGGACTA
            481 TGTCCGGGAA CACAAAGACA ATATTGGCTC CCAGTACCTG CTCAACTGGT GTGTGCAGAT
            541 CGCAAAGGGC ATGAACTACT TGGAGGACCG TCGCTTGGTG CACCGCGACC TGGCAGCCAG
            601 GAACGTACTG GTGAAAACAC CGCAGCATGT CAAGATCACA GATTTTGGGC GGGCCAAACT
            661 GCTGGGTGCG GAAGAGAAAG AATACCATGC AGAAGGAGGC AAAGTGCCTA TCAAGTGGAT
            721 GGCATTGGAA TCAATTTTAC ACAGAATCTA TACCCACCAG AGTGATGTCT GGAGCTACNG
            781 GGTGACCGTT TGNGAGTTGA TGANCTTTGG ATCCNAGCCA TATGACGGAA TCCCTGCCAG
            841 CGNNNTCTCC TCCATCCTGG ANAAAGGANA ANGCCTCCCT CANNCNCCCA TATNNACCAT
            901 CNNTGTCTAC NTNNNCNTGG NCAANNNNTN NNNGNNANNC GNNNNNANTC NCCNNANNNT
          961 NNNNNNNNNN
          //

          Please visit Sequencing and PCR primers for primer information.


          References

          Original, user report and related articles

          original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          2023.05.01

          GNP_filter3_RDBDEP_html_230501.pl